Clinical Trial

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-12-05; most recent amendment 2026-05-01.
Status change: Not Yet Recruiting → Recruiting 2025-06-03
Status change: Recruiting → Not Yet Recruiting 2025-05-13
Status change: Not Yet Recruiting → Recruiting 2025-05-07
Trial Details
NCT Number NCT06727773
Lead Sponsor UNC Lineberger Comprehensive Cancer Center
Collaborators: National Institute on Aging (NIA)
Conditions Breast Cancer, Locally Advanced Breast Cancer, Cognitive Impairment, Cognitive Decline, Cognitive Change, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Enrollment 90 participants
Start Date 2025-08-19
Primary Completion 2029-06-15 (estimated)
Study Completion 2029-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-06